Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lane Labs USA

This article was originally published in The Tan Sheet

Executive Summary

House Government Reform Committee Chairman Dan Burton (R-Ind.) questions FDA's actions against Lane's BeneFin, SkinAnswer and MGN-3 products in a March 27 letter. The agency, in a Dec. 8 complaint filed in Newark, N.J. federal court, is seeking a permanent injunction against the sale of the products, stating they are "unapproved drugs" (1"The Tan Sheet" Dec. 20, 1999, p. 5). Burton notes Lane Labs is testing BeneFin's anti-cancer effects under an IND application, but if "each manufacturer is going to be sued by the FDA for conducting research, then a disincentive has been created." Saying he has received over 300 letters from consumers in support of Lane Labs, the Indiana Republican advises FDA to "create a category of research application specifically tailored to dietary supplements so that research is encouraged...and companies are not at risk for legal action"
Advertisement
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS091068

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel